The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments. </AbstractSection> Copyright Springer-Verlag 2012

Current costs in AF patients are driven by the consequences of AF, while costs for specific treatments for AF are low. The addition of new, effective and safe treatment options could potentially reduce overall healthcare costs in AF. </AbstractSection> Copyright Adis Data Information BV 2010

Alzheimer’s disease (AD) is a leading cause of disability in the elderly, leading to a high burden on caregivers and costs to society. This article describes the current level of data availability regarding the costs of AD in Europe, summarizes and compares findings from previous studies in...

Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. <p> Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...</p>

Background <p> Economic evaluation of treatments in multiple sclerosis (MS) presents a challenge. The disease affects a number of different body functions and leads to severe disability over time, without however a strong effect on mortality. At onset, the majority of patients will have...</p>

Intresse och användning av hälsoekonomiska utvärderingar som underlag vid beslut om pris och subentionering av läkemedel ökar i de flesta länder. Många länder har infört mer eller mindre formella krav på hälsoekonomisk dokumentation inför sådana beslut och ett flertal länder och...

I denna rapport analyseras sambandet mellan priser, marknadsandelar och terapeutisk innovationshöjd för ett antal läkemedel (NCE preparat) introducerade på den svenska marknaden mellan 1987 och 2000. Det finns ett positivt samband mellan innovationshöjd och prispremier vid tidpunkten för...